1. Introduction
Pancreatic cancer remains a highly fatal disease with a 5-year survival rate of less than 10% despite improvements in diagnosis, surgical techniques, and systemic treatments [
1]. Likewise, most patients present with locally advanced (30-35%) or metastatic (50-55%) disease at the time of diagnosis [
1]. Left pancreatectomy (LP), with or without splenectomy, is the surgical technique used to treat tumors in the body and tail of the pancreas [
2]. LP is associated with low mortality (< 3%) but high morbidity (> 30%), usually related to postoperative pancreatic fistula (POPF) [
3]. Implementing the LP by minimally invasive surgery (MIS) (laparoscopic or robotic) has represented a great advance and is considered today's approach of choice. Its main advantages are less bleeding, less need for transfusion, shorter hospital stay, rapid functional recovery, and better postoperative quality of life with the same oncological outcomes and mortality and POPF rates [
3,
4,
5,
6,
7].
Improving the quality of care is an absolute priority for health systems to provide better care and reduce costs, always maintaining efficiency and guaranteeing clinical results with high-quality standards [
8,
9,
10]. One of the alternatives to achieve these objectives is centralized resection of pancreatic cancer, which highlights its complexity, risks, and need for experience and resources [
11,
13].
Centralization policies are usually based on patient thresholds [
14]. Multiple factors can affect clinical results: early diagnosis programs, multidisciplinary teams including advanced endoscopic procedures and interventional radiology, standardized protocols, updated systemic treatments, and surgical interventions with low rates of failure to rescue [
11].
Centralization has several benefits, some directly related to improving clinical results (higher resection rates, fewer complications, and better survival) [
15,
16]. However, beyond these, they include professional development, specialized training, participation in clinical trials, safety improvement, and efficiency in introducing advances in care [
17].
Worldwide centralized care for pancreatic cancer is variable because implementation rates are very heterogeneous, with very few countries able to carry it out satisfactorily. [
14]. The main barriers to centralization are the geographic distance, population density, available resources, experience of health personnel, and resistance to change in practices or national health service delivery models [
13].
From the rejection and concern of low volume centers to see their volume of patients reduced as well as budget allocation and experience, the term regionalization arises as opposed to centralization, since it better reflects the accumulation of cases in centers with higher volume to guarantee adequate support to the hospitals in an area [
11].
A wealth of scientific literature analyzes the clinical outcomes of pancreatic surgery based on patient volume. Like many other countries, the management of pancreatic cancer in Spain has developed in a fragmented manner, without a coordinated effort to centralize care thus far. This study analyzes clinical outcomes related to patient volume at different centers after LP. Our goal is to determine whether our practices align with the standards established in the literature and assess whether centralization's advantages significantly outweigh its disadvantages.
2. Materials and Methods
The SPANDISPAN Project (SPANish DIStal PANcreatectomy) is an observational, prospective, multicenter study focused on LP conducted in Spanish Hepato-Pancreato-Biliary (HPB) Surgery Units over one year, from February 1st, 2022, to January 31st, 2023. Seventy hospitals previously participating in the Spanish Association of Surgery/International Hepato-Pancreato-Biliary Association (AEC/IHPBA) Pancreatic Surgery Survey were contacted via email [
18]. HPB units were defined as high volume if they performed more than 10 LPs annually. A centralization model is employed in one region of Spain; in the other sixteen regions, any hospital may perform LP.
Each participating center assigned a local administrator to oversee data collection and liaison with the overall study coordinator. Local administrators gathered data at their respective hospitals, and a REDCap® database (Research Electronic Data Capture, Vanderbilt University, Nashville, Tennessee, USA) was established for the study.
The study adhered to the Declaration of Helsinki (2013) and was approved by the Clinical Research Ethics Committee of the Hospital General Universitario Dr. Balmis (Alicante, Spain) on April 28th, 2021 (CEIm: Acta 2021-04). Patients provided informed consent before participating in the study, which is reported according to the STROBE guidelines [
19].
The study included any scheduled LP performed during the study period, regardless of diagnosis, in patients over 18 years of age. Exclusion criteria included LP with celiac trunk resection, LP after pancreaticoduodenectomy, or emergency LP. The suspected preoperative diagnosis was based on imaging tests such as CT, MRI, and EUS. The surgical approach utilized could be open or minimally invasive (laparoscopic or robotic), with or without spleen preservation.
2.1. Variables and Definitions
The variables studied include demographic data such as age, sex, body mass index (BMI), history of previous abdominal surgeries, medications, and the ASA (American Society of Anesthesiologists) scale score [
20]. Additional data were collected on biological symptoms, radiological findings, and the surgical approach utilized (open, laparoscopic, or robotic). Conversion is defined as a change from minimally invasive surgery (MIS) to open laparotomy. Spleen preservation refers to using the Warshaw or Kimura techniques, while associated organ resection is the removal of at least one additional organ, excluding the spleen. Intraoperative blood loss and the need for transfusion were also recorded.
Postoperative data included morbidity and mortality, with complications evaluated at 90 days using the Clavien-Dindo classification system [
21]. Complications classified as grade IIIa or higher were considered major. The complications were documented based on medical and nursing clinical notes from each patient’s electronic medical records. Specific definitions applied to pancreatic surgery complications were drawn from the International Study Group on Pancreatic Surgery (ISGPS) guidelines for delayed gastric emptying (DGE) [
22], post-pancreatectomy hemorrhage (PPH) [
23], and POPF [
24].
The resection margins of the specimens were classified according to the Royal College of Pathologists' definitions: R0 (tumor margin ≥ 1 mm), R1 (tumor margin < 1 mm), and R2 (macroscopically positive margin) [
25]. We classified invasive tumors using the TNM classification system (8th edition) [
26]. Reintervention was defined as any unscheduled surgical procedure related to pancreatic resection. Hospital stays and readmissions were measured within 90 days. The histological data collected included tumor size, R status, and the size of the resected pancreas.
We used a reference of 10 patients to categorize participating centers into low and high volumes [
27]. Centers that reported 10 or fewer patients during the study period were classified as low volume, while those that reported more than 10 patients were categorized as high volume.
2.2. Statistical Analysis
Measurements were conducted using Microsoft® Excel for Mac, version 16.49, and SPSS® for Mac, version 26.0 (SPSS Inc., Chicago, Illinois, USA). All calculations were performed with R (version 4.2.1).
Descriptive statistics were computed using frequencies and percentages for categorical data and medians and interquartile ranges (IQR) for continuous data. The IQR represents the range between the first quartile (Q1) and the third quartile (Q3). Categorical variables were described by indicating the number of cases and their respective percentages. The chi-square test was employed to assess the association between two categorical variables. The relevant data were collected and organized in a contingency table, after which the chi-square test with Yates correction was applied. The Mann-Whitney U test was utilized to compare the distributions of two nonparametric continuous variables.
A logistic regression model was implemented to analyze the association between predictor variables and a binary outcome variable, with odds ratios calculated to measure the strength of the association. Point estimates of the odds ratios and their corresponding 95% confidence intervals (95% CI) were generated.
3. Results
This study included 313 patients who underwent LP at 41 centers across Spain over the course of a year. 40.3% of the procedures were performed in high-volume centers (> 10 cases/year). The median number of LPs conducted per center was 7, with an interquartile range (IQR) of 5 to 10.
The median age of the patients was 65 years (IQR 55-74), and 53.4% were women. The mean body mass index (BMI) was 27.5 kg/m² (IQR 24.0-30.7). The most common ASA score among the patients was II, representing 47.6%, and the median Charlson Comorbidity Index was 4 (IQR 2-5).
In terms of tumor location, 40.6% of cases involved the tail of the pancreas. The primary indications for surgery were neuroendocrine tumors, accounting for 31.3% of cases, and pancreatic adenocarcinoma, which comprised 26.8%. The median tumor size was 28 mm (IQR 17- 44).
In 69.3% of the patients, MIS was used, and the most frequently performed procedure was LP with splenectomy, which occurred in 86.6% of the cases. Preservation of the spleen was achieved in 13.4% of patients. The median operative time was 240 minutes (IQR 180-300). Major complications were observed in 21.1% of patients, with postoperative pancreatic fistula (POPF) grades B and C occurring in 20.1% of cases. The 90-day mortality rate was 1.6%. R0 resection was achieved in 92% of the LP.
187 patients were included in the low-volume group from 32 centers (59.7%), while 126 were in the high-volume group from 9 centers (40.3%). Significant differences in preoperative variables were only observed in ASA scores, which were higher in the high-volume group. The distribution by type of tumor and tumoral size did not show statistical differences (
Table 1).
Intraoperatively, minimally invasive surgical techniques, including laparoscopic and robotic approaches, were performed more frequently in high-volume centers. However, the conversion rate was also higher in this group. Using a 60 mm stapler and omental patch following LP was more common in high-volume centers, where intraoperative blood loss was lower (
Table 2).
Postoperatively, the administration of somatostatin was more prevalent in low-volume hospitals. Major complications, assessed according to the Clavien-Dindo classification, were also more frequent in low-volume hospitals. Clinically relevant POPF (CR-POPF) was higher in low-volume hospitals. DGE, PPH, and non-pancreas-related complications were similar in both groups.
No differences were observed in the length of stay or readmission rates between the two groups. There were no differences concerning tumor type, margin status, or the number of lymph nodes harvested (
Table 3).
4. Discussion
In our prospective study involving 313 LPs, 60% were conducted in low-volume centers. Centers that perform more than 10 LPs per year demonstrated a higher percentage of minimally invasive surgeries, experienced fewer complications and CR-POPF, and employed certain technical and management variations. These included using larger staplers, a more frequent application of the omental patch, and a reduced reliance on somatostatin.
Central pancreatic surgery has multiple proven benefits [
13,
14,
15,
16,
17,
28,
29,
30]. Still, manuscripts about this topic usually focus on patients undergoing pancreaticoduodenectomy, as LP is generally regarded as less complex, with lower mortality and morbidity rates [
31]. However, LP is not without complications; for instance, POPF can occur in up to 30% of patients. This complication may lead to more extended hospital stays, increased reoperations, and delays in initiating adjuvant treatment for patients with malignant tumors [
32]. Therefore, centralizing LP could yield advantages like those in more complex surgeries. Successful outcomes are not solely dependent on the surgical technique; having multidisciplinary teams that include 24/7/365 endoscopists, interventional radiologists, and other specialists is crucial for improving patient outcomes [
28].
When we proposed this study, our main question was whether low-volume centers might select fewer complex patients, which could lead to a biased comparison between the two groups. The only difference we observed was that patients from high-volume centers had a higher ASA score. This suggests their greater experience and a more expert multidisciplinary team may enable them to treat more fragile patients. We did not find any other patient or tumor characteristics that distinguished the two groups, which allows for a valid comparison. In a previous benchmarking analysis of our series, we found that low-volume centers also did not select simpler patients, as the number of patients in the low-risk group (BMI < 35 kg/m
2, ASA < III, no multivisceral resection, no previous liver and/or pancreas surgery, use of any surgical approach, and any diagnosis) was similar between low- and high-volume centers [
33].
We want to highlight technical and management aspects that differentiate the two groups. Currently, minimally invasive surgery is recognized as the gold standard for LP, achieving a total rate of 70% that improves the latest published series [
27]. It is logical that higher-volume centers perform more minimally invasive surgeries and are the first to adopt robotic surgery, which will likely become the preferred technique [
34]. An omental patch after LP is a technical trick that is being performed more frequently. Higher-volume groups tend to use this technique more regularly, likely due to their greater experience in pancreatic surgery [
35].
We have no explanation for the differences observed in the use of various sizes of staplers, as there are no significant differences between the two groups concerning the cut area or pancreatic thickness. Furthermore, somatostatin has not demonstrated a decrease in POPF rates and is, therefore, not currently recommended for prophylactic use [
36,
37,
38]. We hypothesize that the higher rate of POPF in low-volume hospitals may explain the increased use of somatostatin in those settings.
This study's limitation lies in its multicenter design, which includes various surgical teams, each following their own protocols. This variability could introduce inconsistencies in data collection and analysis. However, a notable strength of the study is its prospective nature, which when comparing low and high-volume centers. Due to recent data collection shows a high rate (70%) of MIS.
5. Conclusions
In conclusion, 60% of patients underwent surgery in low-volume centers (defined as those with fewer than 10 laparoscopic procedures per year). The findings revealed that high-volume centers had a higher rate of MIS, along with specific technical variations (such as omental patch techniques and stapler lengths), lower intraoperative bleeding, fewer complications, and reduced POPFs compared to low-volume centers. However, it is important to note that low-volume centers still demonstrated acceptable outcomes. Thus, the selective referral of more complex laparoscopic procedures could initiate a gradual centralization of surgical practices.
Funding
This research received no specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Authors' contributions
All authors met the ICMJE authorship criteria. Contributions: (I) Conception and design: Mario Serradilla-Martín, Daniel Aparicio-López, José M. Ramia. (II) Administrative support: All authors. (III) Provision of study materials or patients: All authors. (IV) Collection and assembly of data: Mario Serradilla-Martín, Daniel Aparicio-López, and Cándido F. Alcázar-López. (V) Data analysis and interpretation: Mario Serradilla-Martín, Daniel Aparicio-López, José M. Ramia, Celia Villodre, and Cándido F. Alcázar-López. (VI) Manuscript writing: Daniel Aparicio-López and José M. Ramia. (VII) Final approval of manuscript: All authors.
Institutional Review Board Statement
The study adhered to the Declaration of Helsinki (2013) and was approved by the Clinical Research Ethics Committee of the Dr. Balmis General University Hospital (Alicante, Spain) on April 28th, 2021 (CEIm: Acta 2021-04).
Informed Consent Statement
Patients provided informed consent before participating in the study, which is reported according to the STROBE guidelines.
Data Availability Statement
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Conflicts of Interest
Mario Serradilla-Martín received honoraria from Baxter and Sanofi SA as an adviser last year. The rest of the authors declare no conflicts of interest.
Meeting presentation
The results of this study were presented at the International Hepato-Pancreato-Biliary Surgery World Congress in Cape Town, South Africa, in May 2024.
Abbreviations
The following abbreviations are used in this manuscript:
| AEC/IHPBA |
Spanish Association of Surgery/International Hepato-Pancreato-Biliary Association |
| SPANDISPAN |
SPANish DIStal PANcreatectomy |
| ISGPS |
International Study Group on Pancreatic Surgery |
| POPF |
Postoperative pancreatic fistula |
| MIS |
Minimally invasive surgery |
| HPB |
Hepato-Pancrea-Biliary |
| BMI |
Body Mass Index |
| DGE |
Delayed gastric emptying |
| PPH |
Post-pancreatectomy hemorrhage |
| IQR |
Interquartile range |
| LP |
Left pancreatectomy |
References
- Park W, Chawla A, O'Reilly EM. Pancreatic Cancer: A Review. JAMA. 2021 Sep 7;326(9):851-862. [CrossRef]
- Lillemoe KD, Kaushal S, Cameron JL, Sohn TA, Pitt HA, Yeo CJ. Distal pancreatectomy: indications and outcomes in 235 patients. Ann Surg. 1999 May;229(5):693-8; discussion 698-700. [CrossRef]
- Durin T, Marchese U, Sauvanet A, et al. Defining Benchmark Outcomes for Distal Pancreatectomy: Results of a French Multicentric Study. Ann Surg. 2023 Jul 1;278(1):103-109. [CrossRef]
- van Ramshorst TME, Giani A, Mazzola M, et al. Benchmarking of robotic and laparoscopic spleen-preserving distal pancreatectomy by using two different methods. Br J Surg. 2022 Dec 13;110(1):76-83. [CrossRef]
- Giani A, van Ramshorst T, Mazzola M, et al. Benchmarking of minimally invasive distal pancreatectomy with splenectomy: European multicentre study. Br J Surg. 2022 Oct 14;109(11):1124-1130. [CrossRef]
- Müller PC, Breuer E, Nickel F, et al. Robotic Distal Pancreatectomy: A Novel Standard of Care? Benchmark Values for Surgical Outcomes From 16 International Expert Centers. Ann Surg. 2023 Aug 1;278(2):253-259. [CrossRef]
- Müller PC, Toti JMA, Guidetti C, et al. Benchmarking outcomes for distal pancreatectomy: critical evaluation of four multicenter studies. Langenbecks Arch Surg. 2023 Jun 29;408(1):253. [CrossRef]
- Gero D, Raptis DA, Vleeschouwers W, et al. Defining Global Benchmarks in Bariatric Surgery: A Retrospective Multicenter Analysis of Minimally Invasive Roux-en-Y Gastric Bypass and Sleeve Gastrectomy. Ann Surg. 2019 Nov;270(5):859-867. [CrossRef]
- Lassen K, Nymo LS, Olsen F, Søreide K. Benchmarking of aggregated length of stay after open and laparoscopic surgery for cancers of the digestive system. BJS Open. 2018 Apr 23;2(4):246-253. [CrossRef]
- Bagante F, Ruzzenente A, Beal EW, et al. Complications after liver surgery: a benchmark analysis. HPB (Oxford). 2019 Sep;21(9):1139-1149. [CrossRef]
- Ratnayake B, Pendharkar SA, Connor S, Koea J, Sarfati D, Dennett E, Pandanaboyana S, Windsor JA. Patient volume and clinical outcome after pancreatic cancer resection: A contemporary systematic review and meta-analysis. Surgery. 2022 Jul;172(1):273-283. [CrossRef]
- Elberm H, Ravikumar R, Sabin C, Abu Hilal M, Al-Hilli A, Aroori S, et al. Outcome after pancreaticoduodenectomy for T3 adenocarcinoma: A multivariable analysis from the UK Vascular Resection for Pancreatic Cancer Study Group. Eur J Surg Oncol. 2015 Nov;41(11):1500-7. [CrossRef]
- Shrikhande SV, Shinde RS, Chaudhari VA, Kurunkar SR, Desouza AL, Agarwal V, et al. Twelve Hundred Consecutive Pancreato-Duodenectomies from Single Centre: Impact of Centre of Excellence on Pancreatic Cancer Surgery Across India. World J Surg. 2020 Aug;44(8):2784-2793. [CrossRef]
- Polonski A, Izbicki JR, Uzunoglu FG. Centralization of Pancreatic Surgery in Europe. J Gastrointest Surg. 2019 Oct;23(10):2081-2092. [CrossRef]
- Gooiker GA, Lemmens VE, Besselink MG, Busch OR, Bonsing BA, Molenaar IQ, Tollenaar RA, de Hingh IH, Wouters MW. Impact of centralization of pancreatic cancer surgery on resection rates and survival. Br J Surg. 2014 Jul;101(8):1000-5. [CrossRef]
- Hunger R, Seliger B, Ogino S, Mantke R. Mortality factors in pancreatic surgery: A systematic review. How important is the hospital volume? Int J Surg. 2022 May;101:106640. [CrossRef]
- Ahola R, Sand J, Laukkarinen J. Centralization of Pancreatic Surgery Improves Results: Review. Scand J Surg. 2020 Mar;109(1):4-10. [CrossRef]
- Ramia JM, Serrablo A, Gomez Bravo MA.; Grupo Español de Cirugía Pancreática AEC CE IHPBA. National survey on Pancreatic Surgery Units. Cir Esp (Engl Ed). 2019 May;97(5):254-260. [CrossRef]
- von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007 Oct 20;335(7624):806-8. [CrossRef]
- Ament, R. Origin of the ASA classification. Anesthesiology. 1979 Aug;51(2):179. [CrossRef]
- Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. [CrossRef]
- Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007 Nov;142(5):761-8. [CrossRef]
- Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007 Jul;142(1):20-5. [CrossRef]
- Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017 Mar;161(3):584-591. [CrossRef]
- Campbell F, Cairns A, Duthie F, Feakins R. Dataset for the histopathological reporting of carcinomas of the pancreas, ampulla of Vater and common bile duct. The Royal College of Pathologists. October 2019. Avalibale at: https://www.rcpath.org/static/34910231-c106-4629-a2de9e9ae6f87ac1/G091-Dataset-for-histopathological-reporting-of-carcinomas-of-the-pancreas-ampulla-of-Vater-and-common-bile-duct.pdf. Accessed May 5th, 2025.
- TNM 8th edition. Available at: https://cancerstaging.org/Pages/default.aspx. Accessed May 5th, 2025.
- van der Heijde N, Vissers FL, Manzoni A, et al. Use and outcome of minimally invasive pancreatic surgery in the European E-MIPS registry. HPB (Oxford). 2023 Apr;25(4):400-408. [CrossRef]
- Ghaferi AA, Osborne NH, Birkmeyer JD, Dimick JB. Hospital characteristics associated with failure to rescue from complications after pancreatectomy. J Am Coll Surg. 2010; 211:325–330. [CrossRef]
- Mise Y, Hirakawa S, Tachimori H, Kakeji Y, Kitagawa Y, Komatsu S, et al. Volume- and quality-controlled certification system promotes centralization of complex hepato-pancreatic-biliary surgery. J Hepatobiliary Pancreat Sci. 2023 Jul;30(7):851-862. [CrossRef]
- Hoshijima H, Wajima Z, Nagasaka H, Shiga T. Association of hospital and surgeon volume with mortality following major surgical procedures: Meta-analysis of meta-analyses of observational studies. Medicine (Baltimore). 2019 Nov;98(44):e17712. [CrossRef]
- Khan MA, Muhammad S, Mehdi H, Parveen A, Soomro U, Ali JF, et al. Surgeon's Experience May Circumvent Operative Volume in Improving Early Outcomes After Pancreaticoduodenectomy. Cureus. 2023 Aug 3;15(8):e42927. [CrossRef]
- Lequeu JB, Cottenet J, Facy O, Perrin T, Bernard A, Quantin C. Failure to rescue in patients with distal pancreatectomy: a nationwide analysis of 10,632 patients. HPB (Oxford). 2021 Sep;23(9):1410-1417. [CrossRef]
- Ramia JM, Alcázar-López CF, Villodre-Tudela C, Rubio-García JJ, Hernández B, Aparicio-López D et al. Benchmark Outcomes for Distal Pancreatectomy: A Multicenter Prospective Snapshot Study from the Spanish Distal Pancreatectomy Project (SPANDISPAN). J Am Coll Surg. 2024; 239 (3):288-297. [CrossRef]
- De Pastena M, Esposito A, Paiella S, Montagnini G, Zingaretti CC, Ramera M et al. Nationwide cost-effectiveness and quality of life analysis of minimally invasive distal pancreatectomy. Surg Endosc 2024 Oct;38(10):5881-5890. [CrossRef]
- Ramia JM, de la Plaza R, Adel F, Ramiro C, Arteaga V, Garcia-Parreño J. Wrapping in pancreatic surgery: a systematic review. ANZ J Surg. 2014 Dec;84(12):921-4. [CrossRef]
- Goodsell KE, Chauhan SSB, Pillarisetty VG, Sham JG. Somatostatin Analogs for Preventing Postoperative Pancreatic Fistula: Past Evidence Reveals New Opportunities Ann Surg Oncol 2025 Jun 27. [CrossRef]
- Gaujoux S, Regimbeau JM, Piessen G, Truant S, Foissac F, Barbier L et al. Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial: A FRENCH 007-ACHBT Study Ann Surg 2024 Aug 1;280(2):179-187. [CrossRef]
- Ramia JM, Villodre C, Serradilla-Martín M, Alcazar C, Blanco-Fernández G, Rotellar F et al. Assessing the Potential Difficulty of Left Pancreatectomy: International Modified Delphi Consensus. J Am Coll Surg. 2025 May 9. [CrossRef]
Table 1.
Comparison of preoperative variables between low and high-volume centers.
Table 1.
Comparison of preoperative variables between low and high-volume centers.
| |
Total N=131
|
Low-volume (n ≤ 10) N=187
|
High-volume (n > 10) N=126
|
p value |
| Age, years (IQR) |
65.0 [55.0;74.0] |
64.0 [54.5;73.0] |
67.0 [57.2;75.0] |
0.227 |
Gender, n (%)
Male
Female
|
146 (46.6%) 167 (53.4%)
|
83 (44.4%) 104 (55.6%)
|
63 (50.0%) 63 (50.0%)
|
0.389 |
| Comorbidity Charlson Index, median (IQR) |
4.00 [2.00;5.00] |
3.00 [2.00;5.00] |
4.00 [2.00;5.00] |
0.800 |
| Body Mass Index, kg/m2 (IQR) |
27.5 [24.0;30.7] |
27.1 [23.8;30.1] |
27.9 [24.3;31.0] |
0.268 |
ASA score, n (%)
I
II
III
IV
|
17 (5.43%) 149 (47.6%) 141 (45.0%) 6 (1.92%)
|
13 (6.95%) 92 (49.2%) 76 (40.6%) 6 (3.21%)
|
4 (3.17%) 57 (45.2%) 65 (51.6%) 0 (0.00%)
|
0.038 |
Table 2.
Comparison of intraoperative variables between low and high-volume centers.
Table 2.
Comparison of intraoperative variables between low and high-volume centers.
| |
Total N=313
|
Low-volume (n ≤ 10) N=187
|
High-volume (n > 10) N=126
|
p value |
Surgical technique, n (%)
Left pancreatectomy
RAMPS
Spleen preserving pancreatectomy
|
226 (72.2%) 45 (14.4%) 42 (13.4%)
|
136 (72.7%) 25 (13.4%) 26 (13.9%)
|
90 (71.4%) 20 (15.9%) 13 (12.7%)
|
0.907 |
Approach, n (%)
Laparoscopic
Robotic
Open
|
166 (53%) 51 (16.3%) 96 (30.7%)
|
93 (50.3%) 26 (13.9%) 67 (35.8%)
|
72 (57.2%) 25 (19.8%) 29 (23.0%)
|
0.046 |
| Conversion, n (%) |
23 (10.6%) |
8 (6.67%) |
15 (15.5%) |
0.061 |
Pancreas consistency, n (%)
Soft
Hard
|
183 (58.5%) 130 (41.5%)
|
107 (57.2%) 80 (42.8%)
|
76 (60.3%) 50 (39.7%)
|
0.668 |
| Stapler for closing pancreatic stump (yes) |
278 (88.8%) |
168 (89.8%) |
110 (87.3%) |
0.606 |
Length of stapler, n (%)
45 mm
60 mm
|
15 (5.86%) 234 (91.4%)
|
14 (9.03%) 135 (87.1%)
|
1 (0.99%) 99 (98.0%)
|
0.006 |
| Use of epiploplasty (yes), n (%) |
17 (5.43%) |
3 (1.60%) |
14 (11.1%) |
0.001 |
| Intraoperative loss of blood, ml (IQR) |
120 [50.0;300] |
150 [100;300] |
100 [0.00;288] |
0.003 |
| Intraoperative transfusion (yes), n (%) |
20 (6.39%) |
10 (5.35%) |
10 (7.94%) |
0.495 |
| Other organs resected (not including spleen) (yes), n (%) |
272 (86.9%) |
162 (86.6%) |
110 (87.3%) |
0.999 |
| Operative time, min (IQR) |
240 [180;300] |
240 [180;284] |
240 [190;300] |
0.367 |
| Use of abdominal drain (yes), n (%) |
282 (90.1%) |
173 (92.5%) |
109 (86.5%) |
0.121 |
Table 3.
Comparison of postoperative variables between low and high-volume centers.
Table 3.
Comparison of postoperative variables between low and high-volume centers.
| |
Total N=313
|
Low-volume (n ≤ 10) N=187
|
High-volume (n > 10) N=126 |
p value |
Postoperative complications, n (%)
No
Clavien-Dindo I
Clavien-Dindo II
Clavien-Dindo IIIa
Clavien-Dindo IIIb
Clavien-Dindo IVa
Clavien-Dindo IVb
Clavien-Dindo V
Clavien-Dindo ≥ IIIa
|
180 (57.5%) 86 (27.5%) 59 (18.8%) 48 (15.3%) 14 (4.47%) 8 (2.56%) 1 (0.32%) 3 (0.96%) 66 (21.1%)
|
107 (57.2%) 40 (21.4%) 36 (19.3%) 36 (19.3%) 8 (4.28%) 6 (3.21%) 0 (0.00%) 2 (1.07%) 48 (25.7%)
|
73 (57.9%) 46 (36.5%) 23 (18.3%) 12 (9.52%) 6 (4.76%) 2 (1.59%) 1 (0.79%) 1 (0.79%) 18 (14.3%)
|
0.993 0.005 0.941 0.029 1.000 0.482 0.403 1.000 0.023
|
| Comprehensive Complication Index, median (IQR) |
8.70 [0.00;20.9] |
8.70 [0.00;26.2] |
8.70 [0.00;20.9] |
0.242 |
POPF, n (%)
No
Biochemical
B
C
B + C
|
120 (38.3%) 57 (47.5%) 53 (44.2%) 10 (8.33%) 63 (20.1%)
|
77 (41.2%) 31 (40.3%) 38 (49.4%) 8 (10.4%) 46 (24.6%)
|
43 (34.1%) 26 (60.5%) 15 (34.9%) 2 (4.65%) 17 (13.5%)
|
0.255 0.094 0.024 0.042
|
| POPF, days (IQR) |
16.0 [9.00;30.0] |
20.0 [10.8;30.0] |
15.0 [8.00;26.0] |
0.074 |
Reintervention, n (%)
Interventional radiology
Endoscopic
Surgical
|
25 (7.99%) 5 (1.60%) 5 (1.60%) 22 (7.03%)
|
18 (9.63%) 5 (2.67%) 4 (2.14%) 15 (8.02%)
|
7 (5.56%) 0 (0.00%) 1 (0.79%) 7 (5.56%)
|
0.276 0.085 0.652 0.541
|
| Length of stay, days (IQR) |
7.00 [5.00;9.00] |
7.00 [5.00;9.50] |
7.00 [5.00;9.00] |
0.645 |
| Readmission, n (%) |
69 (22.0%) |
45 (24.1%) |
24 (19.0%) |
0.362 |
Postoperative Diabetes Mellitus, n (%)
No
Worsening
New
|
220 (70.3%)
52 (16.6%)
41 (13.1%) |
123 (65.8%)
35 (18.7%)
29 (15.5%) |
97 (77.0%)
17 (13.5%)
12 (9.52%) |
0.098 |
| Pancreatic exocrine insuffiency, n (%) |
68 (21.7%) |
41 (21.9%) |
27 (21.4%) |
1.000 |
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).